摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-ethyl 1-methyl-1H pyrazole-5-amine | 354795-57-6

中文名称
——
中文别名
——
英文名称
4-ethyl 1-methyl-1H pyrazole-5-amine
英文别名
4-ethyl-2-methyl-2H-pyrazol-3-ylamine;4-Ethyl-1-methyl-1H-pyrazol-5-amine;4-ethyl-2-methylpyrazol-3-amine
4-ethyl 1-methyl-1H pyrazole-5-amine化学式
CAS
354795-57-6
化学式
C6H11N3
mdl
MFCD14657261
分子量
125.173
InChiKey
XZBOXHMZSAQASG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    251.0±20.0 °C(Predicted)
  • 密度:
    1.12±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    43.8
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
    申请人:Chuaqui Claudio
    公开号:US20120040951A1
    公开(公告)日:2012-02-16
    The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    本发明提供了式(I)的化合物,可用作Raf蛋白激酶的抑制剂。本发明还提供了其组合物以及治疗Raf介导疾病的方法。
  • Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists
    申请人:Heptares Therapeutics Limited
    公开号:US10196380B2
    公开(公告)日:2019-02-05
    This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.
    本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂,可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐,其中 Q、R1、R2、R3 和 R4 如本文所定义。
  • Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists
    申请人:Heptares Therapeutics Limited
    公开号:US10385039B2
    公开(公告)日:2019-08-20
    This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof wherein Q, R1, R2, R3 and R4 are as defined herein.
    本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂,可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐,其中 Q、R1、R2、R3 和 R4 如本文所定义。
  • Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor
    申请人:Heptares Therapeutics Limited
    公开号:US10689368B2
    公开(公告)日:2020-06-23
    This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.
    本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂,可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐,其中 Q、R1、R2、R3 和 R4 如本文所定义。
  • Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor
    申请人:Heptares Therapeutics Limited
    公开号:US10961225B2
    公开(公告)日:2021-03-30
    This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.
    本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂,可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐,其中 Q、R1、R2、R3 和 R4 如本文所定义。
查看更多